Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
Holding RZLT?
Track your performance easily
RZLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $6.10
Previous Close$4.99
Volume346.25K
Average Volume (3M)308.45K
Market Cap
$276.23M
Enterprise Value$198.60M
Total Cash (Recent Filing)$80.00M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Nov 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding55,360,000
10 Day Avg. Volume453,475
30 Day Avg. Volume308,455
Standard Deviation0.26
R-Squared0.00234
Alpha0.00142
Financial Highlights & Ratios
Price to Book (P/B)3.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$12.00Price Target Upside146.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Rezolute News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRZ358’s clear and strong efficacy signal in the Phase IIb trial, showing a 74% decrease from baseline in hypoglycemia event rate, boosts confidence in the success of the ongoing Phase III sunRIZE study.
FDA ApprovalThe FDA has completely lifted the partial clinical holds on RZ358 for treating congenital hyperinsulinism (CHI), allowing clinical trials at all doses and in patients over 3 months old.
Financial PositionRezolute remains well-capitalized with approximately $145M in cash, providing financial runway into the second half of 2026 or later.
Bears Say
Clinical TrialsSuccess in clinical trials will be essential for Rezolute to market its products, but clinical success is not guaranteed.
Regulatory IssuesRZ358’s partial clinical hold is based on a preclinical rodent finding that is inconsistent with all human safety data.
RevenueRezolute is not generating revenue and has capital needs that exceed current cash balance.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $0.72 and its highest was $6.10 in the past 12 months.
What is Rezolute’s market cap?
Currently, no data Available
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Rezolute’s earnings last quarter?
Currently, no data Available
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rezolute have?
Rezolute has 55,356,930 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rezolute?
Among the largest hedge funds holding Rezolute’s share is Blackstone Inc.. It holds Rezolute’s shares valued at 8M.
---
Rezolute Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (146.41% Upside)
$12.00 (146.41% Upside)
Hedge Fund Trend
Increased
By 207.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
221.93%
12-Months-Change
Fundamentals
Return on Equity
-58.75%
Trailing 12-Months
Asset Growth
-34.62%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
---
RZLT Stock 12 Month Forecast
Average Price Target
$12.00
▲(146.41% Upside)
Technical Analysis
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+53.95%
reiterated a buy rating 11 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +53.95% per trade.
---